Singapore markets closed

MedinCell S.A. (MDCLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
6.980.00 (0.00%)
At close: 09:42AM EDT

MedinCell S.A.

3 rue des FrEres LumiEre
Jacou 34830
France
33 4 67 02 13 67
https://www.medincell.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees138

Key executives

NameTitlePayExercisedYear born
Mr. Christophe DouatCEO & Chairman of Executive Board425.45kN/A1966
Mr. Franck PouzacheChief People Officer & Member of the Management Board215.43kN/AN/A
Stephane PosticChief Financial OfficerN/AN/AN/A
Julie AlimiHead of LegalN/AN/AN/A
Mr. David HeuzeHead of CommunicationsN/AN/AN/A
Mr. Adolfo Lopez-NoriegaHead of Research & DevelopmentN/AN/AN/A
Mr. Sebastien EnaultChief Business OfficerN/AN/AN/A
Ms. Helen MartinHead of Alliance & Project ManagementN/AN/AN/A
Ms. Quiterie De BeauregardHead of Global Health DevelopmentN/AN/AN/A
Dr. Richard Malamut M.D.Chief Medical OfficerN/AN/A1960
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for organ transplant; mdc-WWM for contraception; mdc-STM for malaria; and mdc-IRM for neuroscience. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.

Corporate governance

MedinCell S.A.’s ISS governance QualityScore as of 1 March 2024 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.